International Journal of Advances in Science, Engineering and Technology(IJASEAT)
.
current issues
Volume-8,Issue-3  ( Jul, 2020 )
Statistics report
Nov
Submitted Papers : 80
Accepted Papers : 10
Rejected Papers : 70
Acc. Perc : 12%
  Journal Paper

Paper Title
L.Acidophillus and Bifidobacterium SPP Contribute in the Treatment of Chronic Hepatitis C Patients

Abstract
Hepatitis C virus is a major leading cause of Liver pathogenesis. Probiotics showed a natural therapeutic activity against liver disorders. The antiviral and the antibacterial responses to L. acidophilus and Bifidobacteria spp in patients with chronic hepatitis C virus is a recommended study. Patients with chronic hepatitis C were treated with probiotics capsule that contains L. acidophilus and Bifidobacterium spp. They administered one capsule per day for a month before HCV treatment, blood and urine samples were collected before and after the given treatment and they were processed for a quantitative estimation of HCV by PCR, identification of bacteria by VITEK2 system and 16S r RNA gene sequencing assay, moreover, the estimation of antibacterial activity of probiotics, as well as counts of leukocytes, CD3 + T cells and CD56 + natural killer cells. Administration of Probiotics capsule enhanced the treatment response rate to HCV treatments as IFN-α and ribavirin by 25%. It had antibacterial activity against five species of the most common bacterial infections also It increased CD3 + cells counts and CD56 + natural killer cells in chronic HCV patients. Administration of probiotics as a capsule before HCV treatment can act as a supportive supplement with antiviral and antibacterial activities. Index Terms - CD3 + ; CD56 + ; Hepatitis C virus; Lactobacillus acidophilus; Bifidobacterium bifidum.


Author - Nanis G.Allam, Mohamed L.Salem, Hassan Elbatae, Maii Moustafa Nabieh

| PDF |
Viewed - 25
| Published on 2017-07-08
   
   
IRAJ Other Journals
IJASEAT updates
Volume-8,Issue-1(Jan, 2020)
The Conference World

JOURNAL SUPPORTED BY